Pharmacy

Per FDA requirements, to order and dispense TIKOSYN retail pharmacies are required to secure a one-time certification. Even if you have been certified prior to 2011, you are required to secure a one-time recertification.

To become (re)certified you must review and follow the TIKOSYN In Pharmacy System (T.I.P.S.™) certification procedures below and (re)enroll in the T.I.P.S. Program:

Review the Prescribing Information, including the Medication Guide and Treatment Guidelines
Complete the TIKOSYN Pharmacy Certification Form
Sign and fax the form to 1-800-788-2637
After 1 to 2 business days, confirm your certification by calling 1-877-TIKOSYN (1-877-845-6796) or visit www.tikosynlist.com. You will need to enter your pharmacy DEA number
Your signature on the TIKOSYN certification form acknowledges that the appropriate staff members in your pharmacy are aware of the procedures for dispensing TIKOSYN
Upon receipt of your certification form, a written confirmation will be sent to you. A TIKOSYN stamp will also be sent to you after certification so that you may stamp prescriptions.
The T.I.P.S. Kit (Procedure Booklet and Display Piece) is available here. Please post the T.I.P.S. program procedures, and TIKOSYN contraindications in your pharmacy.

Through pharmacy certification the pharmacy acknowledges that:

The pharmacist will verify that a prescriber has participated in the TIKOSYN REMS and is confirmed in the Pfizer National TIKOSYN Database before dispensing.
The pharmacist will stamp each prescription for distribution with the T.I.P.S. stamp, verifying that the prescriber is a confirmed participant in the TIKOSYN REMS. The pharmacist will then initial and date the TIKOSYN stamped prescription in the appropriate areas.
The pharmacist will dispense a Medication Guide with each prescription.

Contact us

Should you have any questions regarding the certification program, please call 1-877-TIKOSYN.

TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation (for detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION). TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education (see DOSAGE AND ADMINISTRATION). For full Prescribing information, please click here.